Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study

Abstract EN

Introduction.

Low levels of nasal NO have been associated with increased propensity to rhinosinusitis and respiratory tract infections.

Our objective was to describe nasal NO levels in HIV-infected individuals versus healthy controls and determine possible risk factors for reduced nasal NO levels.

Materials and Methods.

HIV-infected individuals and healthy controls were recruited.

Participants underwent nasal NO testing by standardized methods using a CLD88 chemiluminescence analyzer and completed the Sinonasal Outcome Test-20 (SNOT-20) on symptoms of rhinosinusitis.

Results.

Participants included 41 HIV-infected individuals with suppressed VL on antiretroviral therapy (ART group), 5 HIV-infected individuals with detectable VL off ART (viremic group), and 12 healthy controls (HC group).

Mean nasal NO level was 253 (±77) nL/min in the ART group, 213 (±48) nL/min in the viremic group, and 289 (±68) nL/min in the HC group (p=0.133; ANOVA).

There was no correlation between nasal NO level and VL in viremic individuals (r=-0.200; p=0.747).

Differences were observed in mean total points on the SNOT-20 which were 19 (±16)/100, 18 (±26)/100, and 4 (±4)/100 in the ART, viremic, and HC groups, respectively (p=0.013; ANOVA).

Conclusion.

Healthy individuals, HIV patients on ART, and viremic individuals off ART display similar nasal NO levels.

However, rhinosinusitis symptoms remain prominent despite ART-treatment.